Ivosidenib (AG120)
Phase Ib/II Investigator Initiated Study of the IDH1-Mutant Inhibitor Ivosidenib (AG120) With the BCL2 Inhibitor Venetoclax +/- Azacitidine in IDH1-Mutated Hematologic Malignancies
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1/2
- Enrollment
- 64 patients (estimated)
- Sponsors
- MD Anderson Cancer Center
- Tags
- Antimetabolites, BCL-2 Inhibitor, Hypomethylating Agents (HMA), Isocitrate Dehydrogenase 1 (IDH1) Inhibitor
- Trial Type
- Treatment
- Last Update
- 1 month ago
- SparkCures ID
- 1667
- NCT Identifier
- NCT03471260
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.